Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...
Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...
Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. The Fed is seen as likely to leave ...
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
The Motley Fool on MSN12d
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a DecadeWall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's ...
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...
Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising earnings outlook.
It wants to crush (forget 'turn back") the clock on diversity and inclusion in America. Fighting bac requires looking back - and getting it right this time.
Johnson’s story was first reported by the Wall Street Journal in June, though the newspaper’s reporting relied on anonymous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback